CHMP backs generics for Namenda

EMA's CHMP issued a number of positive opinions on Friday, including a recommendation to approve generic versions of Alzheimer's disease drug memantine, which H. Lundbeck A/S (CSE:LUN) markets as Ebixa in Europe. The committee recommended approval of generic versions of memantine from Mylan Inc. (NASDAQ:MYL) and Actavis Inc. (NYSE:ACT). Lundbeck recorded DKK2.4 billion ($424.2 million) in European sales in 2012. Forest Laboratories Inc. (NYSE:FRX) markets the NMDA receptor antagonist as Namenda in the U.S., where the drug is set to lose patent exclusivity in April 2015. ...